论文部分内容阅读
结肠直肠癌的发病率位居全球恶性肿瘤第二位,每年有超过100万例的新增患者,且每年约有608 000例患者死于转移性结肠直肠癌及其相关的临床并发症[1]。即使采用细胞毒药物联合方案化疗,转移性结肠直肠癌患者的中位生存时间也仅从6个月延长至约2年。分子靶向治疗开启了肿瘤诊疗的个体化时代,同时也为转移性结肠直肠癌患者的治疗提供了新选择。仅2005年至2010年,美国临床肿瘤学会年度进展报告中就有5项与结肠直肠癌相关的靶向治疗研究入选年度重大研究进展,其中
The incidence of colorectal cancer is the second highest in the world with more than 1 million new cases each year, and about 608,000 patients die annually from metastatic colorectal cancer and its associated clinical complications [1 ]. Median survival time in patients with metastatic colorectal cancer was only increased from 6 months to about 2 years, even with cytotoxic drug regimens. Molecular targeted therapy has opened the individualized era of cancer treatment and provided a new option for the treatment of patients with metastatic colorectal cancer. From 2005 to 2010 alone, five major annual progress reports of the American Society of Clinical Oncology were included in the annual major research progress in colorectal cancer-related targeted therapies